Skip to main content
Clinical Trials/CTRI/2025/09/094278
CTRI/2025/09/094278
Not yet recruiting
Phase 4

Comparative Study of Intraperitoneal Instillation of Ropivacaine with Two Different Doses of Dexmedetomidine for Postoperative Analgesia in Patients Undergoing Laparoscopic Cholecystectomy

Naruvi Hospitals1 site in 1 country70 target enrollmentStarted: September 15, 2025Last updated:

Overview

Phase
Phase 4
Status
Not yet recruiting
Sponsor
Naruvi Hospitals
Enrollment
70
Locations
1
Primary Endpoint
To evaluate the duration of analgesia following intraperitoneal

Overview

Brief Summary

This study is a prospective randomized double blind parallel group active controlled trial conducted in patients undergoing elective laparoscopic cholecystectomy. The aim is to compare the efficacy of intraperitoneal ropivacaine combined with two different doses of dexmedetomidine for postoperative analgesia. Patients will be randomly assigned to receive ropivacaine with dexmedetomidine 0.5 microgram per kilogram or ropivacaine with dexmedetomidine 1 microgram per kilogram. The primary outcome is the duration of analgesia measured as time to first rescue analgesic requirement. Secondary outcomes include total analgesic consumption in the first 24 hours, incidence of shoulder pain, sedation scores, and postoperative bowel movements. This study is expected to identify the optimal and safe dose of dexmedetomidine for intraperitoneal use in order to improve postoperative pain relief and reduce opioid related adverse effects.

Study Design

Study Type
Interventional
Allocation
Randomized
Masking
Participant, Investigator and Outcome Assessor Blinded

Eligibility Criteria

Ages
18.00 Year(s) to 65.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • Patients aged 18 to 65 years undergoing elective laparoscopic cholecystectomy ASA physical status I,II.

Exclusion Criteria

  • ASA physical status III or IV.
  • Patients with contraindications to ropivacaine or dexmedetomidine.
  • Patients with chronic pain conditions or on chronic opioid therapy.
  • Patients who are unwilling to participate in the study.

Outcomes

Primary Outcomes

To evaluate the duration of analgesia following intraperitoneal

Time Frame: Continuous monitoring until first rescue analgesic — records exact time (hours and minutes) from end of surgery to first rescue dose. | Pain scores (NPRS) to detect the need for rescue will be recorded at: 0 h (on arrival to PACU), 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 12 h, 18 h and 24 h. | If no rescue analgesic is required within 24 h, duration is censored at 24 h.

administration of ropivacaine with two different doses of

Time Frame: Continuous monitoring until first rescue analgesic — records exact time (hours and minutes) from end of surgery to first rescue dose. | Pain scores (NPRS) to detect the need for rescue will be recorded at: 0 h (on arrival to PACU), 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 12 h, 18 h and 24 h. | If no rescue analgesic is required within 24 h, duration is censored at 24 h.

dexmedetomidine.

Time Frame: Continuous monitoring until first rescue analgesic — records exact time (hours and minutes) from end of surgery to first rescue dose. | Pain scores (NPRS) to detect the need for rescue will be recorded at: 0 h (on arrival to PACU), 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 12 h, 18 h and 24 h. | If no rescue analgesic is required within 24 h, duration is censored at 24 h.

Secondary Outcomes

  • To evaluate the total analgesic consumption in the first 24 hours(postoperatively.)

Investigators

Sponsor
Naruvi Hospitals
Sponsor Class
Research institution and hospital
Responsible Party
Principal Investigator
Principal Investigator

Maneesh V S

Naruvi Hospitals

Study Sites (1)

Loading locations...

Similar Trials